Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,396 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
Almeida L, Neves M, Cardoso E, Melo A. Almeida L, et al. J Clin Pharm Ther. 2009 Feb;34(1):125-7. doi: 10.1111/j.1365-2710.2008.00983.x. J Clin Pharm Ther. 2009. PMID: 19125911
Clinical and epidemiological profile of multiple sclerosis in a reference center in the State of Bahia, Brazil.
Cardoso E, Fukuda T, Pereira J, Seixas J, Miranda R, Rodrigues B, Saback T, Andrade R, Cardoso G, Martinez R, Avena J, Melo A. Cardoso E, et al. Arq Neuropsiquiatr. 2006 Sep;64(3B):727-30. doi: 10.1590/s0004-282x2006000500005. Arq Neuropsiquiatr. 2006. PMID: 17057875
Thus, we held a cross-sectional study over the period from February to May, 2005, in the Multiple Sclerosis Patient Support Center ("Núcleo de Apoio aos Pacientes com Esclerose Múltipla") of Bahia, which included all patients with a diagnosis of MS seen over this pe …
Thus, we held a cross-sectional study over the period from February to May, 2005, in the Multiple Sclerosis Patient Support Center (" …
Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?
Nóbrega AC, Rodrigues B, Torres AC, Enzo A, Melo A. Nóbrega AC, et al. J Neurol Sci. 2007 Feb 15;253(1-2):85-7. doi: 10.1016/j.jns.2006.11.015. Epub 2007 Jan 16. J Neurol Sci. 2007. PMID: 17229441 Clinical Trial.
This study analysed if botulinum toxin type A (BTX-A) decreases drooling in 21 Parkinson's disease patients. BTX-A injections were given in the parotid glands. ...Future trials assessing the level of swallowing dysfunction may be important to establish a
This study analysed if botulinum toxin type A (BTX-A) decreases drooling in 21 Parkinson's disease patients. BTX-A inje …
Lupoid sclerosis: what is the role of antiphospholipid antibodies?
Lima I, Melo A, Brandi IV, Costa O, Santiago M. Lima I, et al. J Clin Rheumatol. 2007 Apr;13(2):85-6. doi: 10.1097/01.rhu.0000260637.95695.40. J Clin Rheumatol. 2007. PMID: 17414536
A multiple sclerosis-like syndrome, also called lupoid sclerosis for having some lupus characteristics, has been described in a few reports. ...We report the case of a patient previously diagnosed with multiple sclerosis who later presented with ANA positivit
A multiple sclerosis-like syndrome, also called lupoid sclerosis for having some lupus characteristics, has been described in a
Botulinum toxin type A in refractory chronic migraine: an open-label trial.
Menezes C, Rodrigues B, Magalhães E, Melo A. Menezes C, et al. Arq Neuropsiquiatr. 2007 Sep;65(3A):596-8. doi: 10.1590/s0004-282x2007000400009. Arq Neuropsiquiatr. 2007. PMID: 17876397 Clinical Trial.
Botulinum toxin type A (BT-A) has been described as an important strategy to various types of pain such as cervical dystonia, myofascial pain syndrome and headache. ...Side effects of BT-A were mild and self limited. We conclude that BT-A seems to be …
Botulinum toxin type A (BT-A) has been described as an important strategy to various types of pain such as cervical dystonia, …
Beta interferons in clinically isolated syndromes: a meta-analysis.
Melo A, Rodrigues B, Bar-Or A. Melo A, et al. Arq Neuropsiquiatr. 2008 Mar;66(1):8-10. doi: 10.1590/s0004-282x2008000100003. Arq Neuropsiquiatr. 2008. PMID: 18392405 Review.
We review and summarize the data of published double-blind, randomized clinical trials to assess, with a meta-analysis the safety and efficacy of beta-interferon on the occurrence of relapses in patients with a first clinical event suggestive of MS. ...
We review and summarize the data of published double-blind, randomized clinical trials to assess, with a meta-analysis the safety and …
Does botulinum toxin injection in parotid glands interfere with the swallowing dynamics of Parkinson's disease patients?
Nóbrega AC, Rodrigues B, Melo A. Nóbrega AC, et al. Clin Neurol Neurosurg. 2009 Jun;111(5):430-2. doi: 10.1016/j.clineuro.2008.12.007. Epub 2009 Jan 31. Clin Neurol Neurosurg. 2009. PMID: 19181440
BACKGROUND: During recent years, sialorrhea in Parkinson's disease (PD) has been treated with botulinum toxin type A (BT-A); however, there are no data describing its effects on swallowing dynamics in this group of patients. ...METHODS: Sixteen patients with diurnal …
BACKGROUND: During recent years, sialorrhea in Parkinson's disease (PD) has been treated with botulinum toxin type A (BT-A); h …
Does levodopa improve swallowing dysfunction in Parkinson's disease patients?
Menezes C, Melo A. Menezes C, et al. J Clin Pharm Ther. 2009 Dec;34(6):673-6. doi: 10.1111/j.1365-2710.2009.01031.x. J Clin Pharm Ther. 2009. PMID: 20175800
METHODS: A systematic review of the literature and a meta-analysis were performed. All studies referring to levodopa and swallowing dysfunction that provided direct data or data that could be transformed into mean +/- standard deviation were considered for analysis. …
METHODS: A systematic review of the literature and a meta-analysis were performed. All studies referring to levodopa and swall …
Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine.
Magalhães E, Menezes C, Cardeal M, Melo A. Magalhães E, et al. Clin Neurol Neurosurg. 2010 Jul;112(6):463-6. doi: 10.1016/j.clineuro.2010.02.004. Epub 2010 Apr 18. Clin Neurol Neurosurg. 2010. PMID: 20399553 Clinical Trial.
OBJECTIVE: To compare the effects of botulinum toxin type A with those of amitriptyline on the treatment of chronic daily migraines. ...A reduction of at least 50% in the number of days of pain was recorded in 67.8% of the patients in the BTX-A group and 72% …
OBJECTIVE: To compare the effects of botulinum toxin type A with those of amitriptyline on the treatment of chronic daily migraines. …
Association between allergies and multiple sclerosis: a systematic review and meta-analysis.
Monteiro L, Souza-Machado A, Menezes C, Melo A. Monteiro L, et al. Acta Neurol Scand. 2011 Jan;123(1):1-7. doi: 10.1111/j.1600-0404.2010.01355.x. Acta Neurol Scand. 2011. PMID: 20456246 Review.
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system that expresses a typical type 1 immune response (Th1). ...A total of 1010 articles were retrieved from search, and ten epidemiological studies were included in the analysis. The results …
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system that expresses a typical type 1 immune response (Th1 …
1,396 results
Jump to page
Feedback